Read this in an investor's daily journal today:
Merrill Lynch analyst Eric Ende wrote the most likely outcome is that Tysabri re-enters the market in six months with a single-agent use (i.e., no avonex), a two-year dosing limit and a black-box safety warning.
And further, " In this case, Tysabri sales could be reduced by more than 50%". I'd say probably more like 90% reduction. I personally really wanted to use it, but I doubt my wife would let me try again even if they do bring it back to market.